2022-04-012023-03-312023-03-31false13062850E RAVINDRAN LTD2023-10-31iso4217:GBPxbrli:pure130628502022-04-01130628502023-03-31130628502022-04-012023-03-31130628502020-12-04130628502022-03-31130628502020-12-042022-03-3113062850bus:SmallEntities2022-04-012023-03-3113062850bus:AuditExempt-NoAccountantsReport2022-04-012023-03-3113062850bus:FullAccounts2022-04-012023-03-3113062850bus:PrivateLimitedCompanyLtd2022-04-012023-03-3113062850core:WithinOneYear2023-03-3113062850core:AfterOneYear2023-03-3113062850core:WithinOneYear2022-03-3113062850core:AfterOneYear2022-03-3113062850core:ShareCapital2023-03-3113062850core:SharePremium2023-03-3113062850core:RevaluationReserve2023-03-3113062850core:OtherReservesSubtotal2023-03-3113062850core:RetainedEarningsAccumulatedLosses2023-03-3113062850core:ShareCapital2022-03-3113062850core:SharePremium2022-03-3113062850core:RevaluationReserve2022-03-3113062850core:OtherReservesSubtotal2022-03-3113062850core:RetainedEarningsAccumulatedLosses2022-03-3113062850core:LandBuildings2023-03-3113062850core:PlantMachinery2023-03-3113062850core:Vehicles2023-03-3113062850core:FurnitureFittings2023-03-3113062850core:OfficeEquipment2023-03-3113062850core:NetGoodwill2023-03-3113062850core:IntangibleAssetsOtherThanGoodwill2023-03-3113062850core:ListedExchangeTraded2023-03-3113062850core:UnlistedNon-exchangeTraded2023-03-3113062850core:LandBuildings2022-03-3113062850core:PlantMachinery2022-03-3113062850core:Vehicles2022-03-3113062850core:FurnitureFittings2022-03-3113062850core:OfficeEquipment2022-03-3113062850core:NetGoodwill2022-03-3113062850core:IntangibleAssetsOtherThanGoodwill2022-03-3113062850core:ListedExchangeTraded2022-03-3113062850core:UnlistedNon-exchangeTraded2022-03-3113062850core:LandBuildings2022-04-012023-03-3113062850core:PlantMachinery2022-04-012023-03-3113062850core:Vehicles2022-04-012023-03-3113062850core:FurnitureFittings2022-04-012023-03-3113062850core:OfficeEquipment2022-04-012023-03-3113062850core:NetGoodwill2022-04-012023-03-3113062850core:IntangibleAssetsOtherThanGoodwill2022-04-012023-03-3113062850core:ListedExchangeTraded2022-04-012023-03-3113062850core:UnlistedNon-exchangeTraded2022-04-012023-03-3113062850core:MoreThanFiveYears2022-04-012023-03-3113062850core:Non-currentFinancialInstruments2023-03-3113062850core:Non-currentFinancialInstruments2022-03-3113062850dpl:CostSales2022-04-012023-03-3113062850dpl:DistributionCosts2022-04-012023-03-3113062850core:LandBuildings2022-04-012023-03-3113062850core:PlantMachinery2022-04-012023-03-3113062850core:Vehicles2022-04-012023-03-3113062850core:FurnitureFittings2022-04-012023-03-3113062850core:OfficeEquipment2022-04-012023-03-3113062850dpl:AdministrativeExpenses2022-04-012023-03-3113062850core:NetGoodwill2022-04-012023-03-3113062850core:IntangibleAssetsOtherThanGoodwill2022-04-012023-03-3113062850dpl:GroupUndertakings2022-04-012023-03-3113062850dpl:ParticipatingInterests2022-04-012023-03-3113062850dpl:GroupUndertakingscore:ListedExchangeTraded2022-04-012023-03-3113062850core:ListedExchangeTraded2022-04-012023-03-3113062850dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-04-012023-03-3113062850core:UnlistedNon-exchangeTraded2022-04-012023-03-3113062850dpl:CostSales2020-12-042022-03-3113062850dpl:DistributionCosts2020-12-042022-03-3113062850core:LandBuildings2020-12-042022-03-3113062850core:PlantMachinery2020-12-042022-03-3113062850core:Vehicles2020-12-042022-03-3113062850core:FurnitureFittings2020-12-042022-03-3113062850core:OfficeEquipment2020-12-042022-03-3113062850dpl:AdministrativeExpenses2020-12-042022-03-3113062850core:NetGoodwill2020-12-042022-03-3113062850core:IntangibleAssetsOtherThanGoodwill2020-12-042022-03-3113062850dpl:GroupUndertakings2020-12-042022-03-3113062850dpl:ParticipatingInterests2020-12-042022-03-3113062850dpl:GroupUndertakingscore:ListedExchangeTraded2020-12-042022-03-3113062850core:ListedExchangeTraded2020-12-042022-03-3113062850dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2020-12-042022-03-3113062850core:UnlistedNon-exchangeTraded2020-12-042022-03-3113062850core:NetGoodwill2023-03-3113062850core:IntangibleAssetsOtherThanGoodwill2023-03-3113062850core:LandBuildings2023-03-3113062850core:PlantMachinery2023-03-3113062850core:Vehicles2023-03-3113062850core:FurnitureFittings2023-03-3113062850core:OfficeEquipment2023-03-3113062850core:AfterOneYear2023-03-3113062850core:WithinOneYear2023-03-3113062850core:ListedExchangeTraded2023-03-3113062850core:UnlistedNon-exchangeTraded2023-03-3113062850core:ShareCapital2023-03-3113062850core:SharePremium2023-03-3113062850core:RevaluationReserve2023-03-3113062850core:OtherReservesSubtotal2023-03-3113062850core:RetainedEarningsAccumulatedLosses2023-03-3113062850core:NetGoodwill2022-03-3113062850core:IntangibleAssetsOtherThanGoodwill2022-03-3113062850core:LandBuildings2022-03-3113062850core:PlantMachinery2022-03-3113062850core:Vehicles2022-03-3113062850core:FurnitureFittings2022-03-3113062850core:OfficeEquipment2022-03-3113062850core:AfterOneYear2022-03-3113062850core:WithinOneYear2022-03-3113062850core:ListedExchangeTraded2022-03-3113062850core:UnlistedNon-exchangeTraded2022-03-3113062850core:ShareCapital2022-03-3113062850core:SharePremium2022-03-3113062850core:RevaluationReserve2022-03-3113062850core:OtherReservesSubtotal2022-03-3113062850core:RetainedEarningsAccumulatedLosses2022-03-3113062850core:NetGoodwill2020-12-0413062850core:IntangibleAssetsOtherThanGoodwill2020-12-0413062850core:LandBuildings2020-12-0413062850core:PlantMachinery2020-12-0413062850core:Vehicles2020-12-0413062850core:FurnitureFittings2020-12-0413062850core:OfficeEquipment2020-12-0413062850core:AfterOneYear2020-12-0413062850core:WithinOneYear2020-12-0413062850core:ListedExchangeTraded2020-12-0413062850core:UnlistedNon-exchangeTraded2020-12-0413062850core:ShareCapital2020-12-0413062850core:SharePremium2020-12-0413062850core:RevaluationReserve2020-12-0413062850core:OtherReservesSubtotal2020-12-0413062850core:RetainedEarningsAccumulatedLosses2020-12-0413062850core:AfterOneYear2022-04-012023-03-3113062850core:WithinOneYear2022-04-012023-03-3113062850core:Non-currentFinancialInstrumentscore:CostValuation2022-04-012023-03-3113062850core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-04-012023-03-3113062850core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-04-012023-03-3113062850core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-04-012023-03-3113062850core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-04-012023-03-3113062850core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-04-012023-03-3113062850core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-04-012023-03-3113062850core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-04-012023-03-3113062850core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-04-012023-03-3113062850core:Non-currentFinancialInstrumentscore:CostValuation2023-03-3113062850core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-03-3113062850core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-03-3113062850core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-03-3113062850core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-03-3113062850core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-03-3113062850core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-03-3113062850core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-03-3113062850core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-03-3113062850core:Non-currentFinancialInstrumentscore:CostValuation2022-03-3113062850core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-03-3113062850core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-03-3113062850core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-03-3113062850core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-03-3113062850core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-03-3113062850core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-03-3113062850core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-03-3113062850core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-03-3113062850bus:Director12022-04-012023-03-3113062850bus:Director22022-04-012023-03-31

E RAVINDRAN LTD

Registered Number
13062850
(England and Wales)

Unaudited Financial Statements for the Year ended
31 March 2023

E RAVINDRAN LTD
Company Information
for the year from 1 April 2022 to 31 March 2023

Directors

Dr Eassun Ravindran
Dr Celine Reynolds

Registered Address

2 Wynbury Road
Gateshead
NE9 6TS

Registered Number

13062850 (England and Wales)
E RAVINDRAN LTD
Statement of Financial Position
31 March 2023

Notes

2023

2022

£

£

£

£

Fixed assets
Tangible assets71,9591,591
1,9591,591
Current assets
Debtors917,11624,741
Cash at bank and on hand101,032120,094
118,148144,835
Creditors amounts falling due within one year10(60,675)(42,306)
Net current assets (liabilities)57,473102,529
Total assets less current liabilities59,432104,120
Net assets59,432104,120
Capital and reserves
Called up share capital100100
Profit and loss account59,332104,020
Shareholders' funds59,432104,120
The financial statements were approved and authorised for issue by the Board of Directors on 31 October 2023, and are signed on its behalf by:
Dr Eassun Ravindran
Director
Registered Company No. 13062850
E RAVINDRAN LTD
Notes to the Financial Statements
for the year ended 31 March 2023

1.Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
2.Compliance with applicable reporting framework
These financial statements have been prepared in compliance with FRS 102 Section 1A, The Financial Reporting Standard applicable in the UK and Republic of Ireland.
3.Principal activities
The principal activity of the company during the year was that of dentistry.
4.Basis of measurement used in financial statements
The financial statements have been prepared on the historical cost basis.
5.Accounting policies
Property, plant and equipment policy
Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
Revenue recognition policy
The revenue shown in the profit and loss account represents income receivable from dental treatments carried out during the period. Revenue in respect of dental treatment uncompleted at the year end date is recognised by reference to the state of completion.
Taxation policy
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amount of tax expected to pay or recover using the tax rates and laws that have been enacted, or substantively enacted, at the reporting date.
Employee benefits policy
Contributions to defined contribution plans are expensed in the period to which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund. When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised as a finance cost in profit or loss in the period in which it arises.
Going concern
Following the challenges arising as a consequence of the Covid-19 pandemic in 2020/21, more latterly the UK economy has been impacted by rising inflation, interest rates and energy costs, exacerbated by the war in Ukraine. All these matters have impacted the company’s trading results to a greater or lesser extent. At the date of signing these financial statements, the directors have considered the effect of these matters on the company with the information available to it, and do not believe that it will affect the ability of the company to continue to trade for the foreseeable future. On this basis, the directors have prepared these financial statements on a going concern basis.
6.Employee information

20232022
Average number of employees during the year22
7.Property, plant and equipment

Plant & machinery

Total

££
Cost or valuation
At 01 April 222,1642,164
Additions986986
At 31 March 233,1503,150
Depreciation and impairment
At 01 April 22573573
Charge for year618618
At 31 March 231,1911,191
Net book value
At 31 March 231,9591,959
At 31 March 221,5911,591
8.Description of nature of transactions and balances with related parties
During the period, the directors made available a loan to the company. This loan was interest free and repayable on demand. At the yearend, the balance on the loan was £30,595 (2022: £568).
9.Debtors

2023

2022

££
Trade debtors / trade receivables17,11624,741
Total17,11624,741
10.Creditors within one year

2023

2022

££
Trade creditors / trade payables280-
Taxation and social security28,30040,838
Other creditors30,595568
Accrued liabilities and deferred income1,500900
Total60,67542,306